HealthTech on Steroids: KIIN.Bio secures multimillion funding for AI-driven drug design.
The German startup KIIN.Bio has closed a fresh multimillion-euro investment round to develop its AI-powered platform for accelerated drug discovery.
At the core of their technology is a system that models the behavior of proteins, molecules, and biological interactions — helping researchers find promising drug candidates significantly faster. AI replaces long laboratory cycles and expensive experimental phases.
KIIN.Bio operates at the intersection of bioinformatics, molecular modeling, and generative AI. Their platform is already being used to search for treatments in oncology, immunology, and rare diseases.
Investors make no secret of their ambition: the goal is to create a European counterpart to Recursion, Insilico, or Exscientia — a company capable of transforming the global pharmaceutical industry.
HealthTech is becoming the new DeepTech. AI no longer just accelerates research — it designs molecules that were once considered impossible.
Source: Trending Topics
